Clinical trials: Duodenum Disease, open to volunteers
Peptic Ulcer
Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.
- Trial name
- NCT06439563
- Testing
- JP-1366 10 mg, Lanston Capsule 15 mg
- Where
- South Korea
- Volunteers
- 364 people
- Sponsor
- Onconic Therapeutics Inc.
Gastric Ulcer
Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
- Trial name
- NCT07385235
- Testing
- AD-115A, AD-1151
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Addpharma Inc.
Peptic Ulcer, NSAID-Induced Peptic Ulcer
Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice
This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea.
- Trial name
- NCT07558707
- Where
- South Korea
- Volunteers
- 7,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma
Study of SGR-1505 in Mature B-Cell Neoplasms
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
- Conditions
- Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
- Trial name
- NCT05544019
- Testing
- SGR-1505
- Where
- 36 sites in United States, France and 6 more
- Volunteers
- 98 people
- Sponsor
- Schrödinger, Inc.
Acute Gastrointestinal Bleeding
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute…
- Trial name
- TREET (NCT06188585)
- Testing
- UI-EWD, Conventional therapy
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 278 people
- Sponsor
- Medtronic - MITG
Gastric Ulcer
Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer
A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer
- Trial name
- NCT07730138
- Testing
- DWP14012 40mg (Fexuprazan), Lansoprazole 30mg
- Where
- 2 sites in Indonesia, South Korea
- Volunteers
- 384 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Typ 2 Diabetes, Obesity
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity
Approval study Trans-Duodenal Barrier The goal of this clinical trial is to determin the safety and performance of the newly developed Trans-Duodenal Barrier in adult Tryp 2 diabetic and obese patients.
- Conditions
- Typ 2 Diabetes, Obesity, Obesity Type 2 Diabetes Mellitus, MASH
- Trial name
- LuST (NCT07417683)
- Testing
- endoscopic implant
- Where
- 8 sites in Germany
- Volunteers
- 126 people
- Sponsor
- Trans-Duodenal Concepts GmbH
Reflux Esophagitis (RE)
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
- Trial name
- NCT06850480
- Testing
- JP-1366 simulation tablets, Esomeprazole Magnesium (Nexium) simulation tablets
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Celiac Disease
Study of DONQ52 in Active Celiac Disease
The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in…
- Trial name
- NCT07239336
- Testing
- Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52
- Where
- 74 sites in United States, Australia and 1 more
- Volunteers
- 92 people
- Sponsor
- Chugai Pharmaceutical
Reflux Esophagitis (RE)
A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.
- Trial name
- NCT07010107
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Gastric Outlet Obstruction, Small Bowel Obstruction
GT Metabolic Magnet System in Adults With Gastrointestinal Disorders
Evaluate the performance and safety of the GT Metabolic Magnet System for the creation of side-to-side compression anastomosis in the stomach and/or small bowel in conditions requiring an anastomosis as part of the underlying…
- Conditions
- Gastric Outlet Obstruction, Small Bowel Obstruction, Superior Mesenteric Artery Syndrome
- Trial name
- NCT07317076
- Testing
- Magnet System
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- GT Metabolic Solutions, Inc.